Candel Therapeutics, INC Form 4 insider transactions

Charles Schoch, Interim CFO of Candel Therapeutics, sold 8,897 shares of common stock on July 11, 2024, to cover tax withholding obligations related to vesting restricted stock units.

William Garrett Nichols, Chief Medical Officer of Candel Therapeutics, sold 9,769 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Francesca Barone, Chief Scientific Officer of Candel Therapeutics, sold 12,645 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Director Joseph C. Papa acquired stock options for 14,240 shares of Candel Therapeutics, Inc. on June 26, 2024.

Director Diem Nguyen acquired 14,240 stock options in Candel Therapeutics on June 26, 2024.

Gary J. Nabel, a director of Candel Therapeutics, acquired stock options for 14,240 shares on June 26, 2024.

Director Christopher Martell acquired stock options for 14,240 shares of Candel Therapeutics on June 26, 2024.

Paul B. Manning, a director of Candel Therapeutics, acquired stock options exercisable for 14,240 shares of common stock on June 26, 2024.

Nicoletta Loggia, a director of Candel Therapeutics, acquired stock options for 14,240 shares on June 26, 2024.

Director Renee Gaeta reports acquisition of stock options in Candel Therapeutics.

Director Edward J. Benz Jr. of Candel Therapeutics, Inc. reports acquisition of stock options.